Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) CEO Howard W. Robin sold 14,881 shares of Nektar Therapeutics stock in a transaction dated Monday, August 19. The shares were sold at an average price of $1.28, for a total value of $19,047.68. Following the sale, the chief executive officer now directly owns 848,358 shares of the company’s stock, valued at approximately $1,085,898.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this hyperlink.

Nektar Therapeutics shares down 0.8%

Shares of NKTR opened at $1.27 on Thursday. The company has a 50-day moving average price of $1.26 and a 200-day moving average price of $1.20. Nektar Therapeutics has a 12-month low of $0.41 and a 12-month high of $1.93. The company has a market cap of $233.71 million, a price/earnings ratio of -1.38, and a beta of 0.66.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last released its earnings results on Thursday, August 8. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Nektar Therapeutics had a negative net margin of 195.02% and a negative return on equity of 107.31%. The company had revenue of $23.49 million during the quarter, compared to the consensus estimate of $17.24 million. During the same period last year, the company posted ($0.27) EPS. As a group, research analysts expect Nektar Therapeutics to post -0.84 EPS for the current fiscal year.

Institutional investors weigh in on Nektar Therapeutics

Hedge funds and other institutional investors have made recent changes to their holdings of shares. Victory Capital Management Inc. purchased a new stake in shares of Nektar Therapeutics in the 2nd quarter worth approximately $29,000. Values ​​First Advisors Inc. purchased a new stake in shares of Nektar Therapeutics in the 2nd quarter worth approximately $56,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Nektar Therapeutics in the 1st quarter worth approximately $63,000. SG Americas Securities LLC increased its stake in shares of Nektar Therapeutics by 63.0% in the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 28,338 shares in the last quarter. Finally, Mackenzie Financial Corp. purchased in the fourth quarter a new stake in shares of Nektar Therapeutics worth approximately $42,000. Institutional investors own 75.88% of the company’s shares.

Changes in analyst ratings

Separately, Rodman & Renshaw assumed coverage on Nektar Therapeutics in a research note on Friday, June 28th. They set a “buy” rating and a $2.00 price target on the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $1.50.

View our latest stock analysis for Nektar Therapeutics

Company Profile of Nektar Therapeutics

(Get free report)

Nektar Therapeutics, a biopharmaceutical company, is focused on the discovery and development of immunotherapy drugs in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in Phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as a Phase 2b clinical trial for the treatment of atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in Phase 1 clinical trial to enhance the immune system’s natural ability to fight cancer.

Read more

Get daily news and reviews for Nektar Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Nektar Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.